# US 2002/0160389 A1 · Method for generating a library of mutant oligonucleotides using the linear cyclic amplification reaction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0160389 A1
- Document ID: US20020160389A1
- Status: Published application
- Kind: A1
- Application number: 10/008,620
- Filed: 2001-12-04
- Published: 2002-10-31
- Earliest claimed: 2000-12-04
- Assignees: Genencor International, Inc.
- Inventors: Ana M. Rodriguez; Huaming Wang
- Web page: https://patentgrep.com/patent/US20020160389A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides for a method of producing mutant nucleic acid molecules comprising preparing a first and second oligonucleotide corresponding to two different mutations in a template nucleic acid, mixing the oligonucleotides with a template to which they correspond so as to hybridize and subjecting the mixture to the linear cyclic amplification reaction. The invention also provides a method of producing libraries of mutant nucleic acids using multiple site directed primers. The present invention is particularly well suited for the development of libraries of mutant nucleic acids.

## Claims

### Claim 1

A method of producing a library of mutant nucleic acid molecules comprising:
(a) obtaining a template nucleic acid;
(b) preparing a first oligonucleotide corresponding to a first desired mutation within said template nucleic acid;
(c) preparing a second oligonucleotide corresponding to a second desired mutation within said template nucleic acid;
(d) mixing the oligonucleotides prepared in said steps (b) and (c) so as to hybridize said oligonucleotides to said template nucleic acid;
(e) subjecting the mixture of step (d) to the linear cyclic amplification reaction to produce a library of mutant template nucleic acids.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said oligonucleotides in said steps (b) and (c) are discontiguous.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said step first and second oligonucleotides are present in less than saturation concentration.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the mixture of said step (d) further comprises non-mutagenic oligonucleotides corresponding to either or both of said first and second oligonucleotides.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said template nucleic acid corresponds to a desired protein product.

### Claim 6 (depends on 4)

The method according to claim 4, wherein said protein product comprises an enzyme, hormone, vaccine, peptide therapeutic or antibody.

### Claim 7 (depends on 4)

The method according to claim 4, further comprising the steps of:
(f) transforming said mutant template nucleic acids from said library into a competent host cell;
(g) expressing protein corresponding to said mutant nucleic acids in said host cell;
(h) screening said expressed proteins for desired characteristics.

### Claim 8

A method for producing a library of mutant nucleic acid molecules comprising the steps of:
(a) obtaining a template nucleic acid;
(b) preparing two or more primers corresponding to the template nucleic acid, wherein at least one primer is in opposite orientation to the remaining primers and at least one primer is a mutagenic primer corresponding to a desired mutation;
(c) mixing the primers in said step (b) so as to hybridize said primers to said template nucleic acid; and
(d) subjecting the mixture of step (c) to the linear cyclic amplification reaction to produce a library of mutant template nucleic acids.

### Claim 9 (depends on 8)

The method of claim 8, wherein said two or more primers comprises 3 to 15 primers or 4 to 7 primers.

### Claim 10 (depends on 8)

The method of claim 8, wherein said primers in said step (b) are discontiguous.

### Claim 11 (depends on 8)

The method according to claim 8, wherein said primers in step (b) are present in less than saturation concentration.

### Claim 12 (depends on 8)

The method of claim 8, wherein all said primers in step(b) are mutagenic primers.

### Claim 13 (depends on 8)

The method of claim 8, wherein said at least one mutagenic primer comprises 1 to 12 nucleotide mutations.

### Claim 14 (depends on 8)

The method of claim 8, wherein said at least one mutagenic primer encodes 1 to 4 amino acid mutations.

### Claim 15 (depends on 8)

The method according to claim 8, wherein said template nucleic acid corresponds to a desired protein product.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said protein product comprises an enzyme, hormone, vaccine, peptide therapeutic or antibody.

### Claim 17 (depends on 8)

The method according to claim 8, further comprising the steps of:
(e) transforming said mutant template nucleic acids from said library into a competent host cell;
(f) expressing protein corresponding to said mutant nucleic acids in said host cell; and
(g) screening said expressed proteins for desired characteristics.
